SG11201701033QA - An improved expression cassette for packaging and expression of variant factor viii for the treatment of hemostasis disorders - Google Patents
An improved expression cassette for packaging and expression of variant factor viii for the treatment of hemostasis disordersInfo
- Publication number
- SG11201701033QA SG11201701033QA SG11201701033QA SG11201701033QA SG11201701033QA SG 11201701033Q A SG11201701033Q A SG 11201701033QA SG 11201701033Q A SG11201701033Q A SG 11201701033QA SG 11201701033Q A SG11201701033Q A SG 11201701033QA SG 11201701033Q A SG11201701033Q A SG 11201701033QA
- Authority
- SG
- Singapore
- Prior art keywords
- expression
- packaging
- treatment
- factor viii
- variant factor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/007—Vectors comprising a special translation-regulating system cell or tissue specific
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462036936P | 2014-08-13 | 2014-08-13 | |
PCT/US2015/045142 WO2016025764A2 (en) | 2014-08-13 | 2015-08-13 | An improved expression cassette for packaging and expression of variant factor viii for the treatment of hemostasis disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201701033QA true SG11201701033QA (en) | 2017-03-30 |
Family
ID=55304765
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201701033QA SG11201701033QA (en) | 2014-08-13 | 2015-08-13 | An improved expression cassette for packaging and expression of variant factor viii for the treatment of hemostasis disorders |
Country Status (11)
Country | Link |
---|---|
US (1) | US11014975B2 (en) |
EP (1) | EP3180022A4 (en) |
JP (2) | JP2018506261A (en) |
CN (1) | CN107427557B (en) |
AU (1) | AU2015301598B2 (en) |
BR (1) | BR112017002781A2 (en) |
CA (1) | CA2958141A1 (en) |
SA (1) | SA517380883B1 (en) |
SG (1) | SG11201701033QA (en) |
WO (1) | WO2016025764A2 (en) |
ZA (1) | ZA201701039B (en) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115074366A (en) * | 2015-04-16 | 2022-09-20 | 埃默里大学 | Recombinant promoter and vector for protein expression in liver and application thereof |
EP3294309A4 (en) * | 2015-05-14 | 2019-01-16 | St. Jude Children's Research Hospital, Inc. | Nucleic acid molecules containing spacers and methods of use thereof |
AU2016338565B2 (en) | 2015-10-14 | 2021-11-18 | Audentes Therapeutics, Inc. | Nucleic acid molecules containing spacers and methods of use thereof |
PE20231949A1 (en) * | 2015-10-30 | 2023-12-05 | Spark Therapeutics Inc | VARIANTS OF FACTOR VIII REDUCED WITH CpG, COMPOSITIONS AND METHODS AND USES FOR THE TREATMENT OF HEMOSTASY DISORDERS |
BR112018009732A8 (en) | 2015-11-13 | 2019-02-26 | Baxalta GmbH | polynucleotide, adeno-associated virus vector, adeno-associated virus particle, host cell, methods for producing an adeno-associated virus particle, for treating hemophilia a, for transducing a host cell, and use of a virus particle adeno-associated? |
SG10202106307UA (en) | 2015-11-13 | 2021-07-29 | Takeda Pharmaceuticals Co | Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a |
JP2020533276A (en) * | 2017-08-01 | 2020-11-19 | スパーク セラピューティクス インコーポレイテッドSpark Therapeutics, Inc. | Factor VIII (FVIII) gene therapy |
WO2019222682A1 (en) | 2018-05-18 | 2019-11-21 | Bioverativ Therapeutics Inc. | Methods of treating hemophilia a |
CN108795986A (en) * | 2018-05-31 | 2018-11-13 | 深圳市免疫基因治疗研究院 | A kind of haemophilia A slow virus carrier, slow virus and its preparation method and application |
TW202039546A (en) | 2019-01-16 | 2020-11-01 | 美商巴克斯歐塔公司 | Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a |
CN111218446B (en) * | 2019-12-25 | 2023-03-28 | 劲帆生物医药科技(武汉)有限公司 | Liver specificity promoter and application thereof |
WO2022241041A2 (en) * | 2021-05-11 | 2022-11-17 | City Of Hope | Adeno-associated virus compositions and methods of use thereof |
WO2024007978A1 (en) * | 2022-07-07 | 2024-01-11 | 深圳新诺微环生物科技有限公司 | Linker peptide, fviii protein containing linker peptide or variant thereof, and use thereof |
CN115948408A (en) * | 2022-09-23 | 2023-04-11 | 上海信致医药科技有限公司 | Improved human coagulation factor VIII gene expression cassette and application thereof |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6114148C1 (en) | 1996-09-20 | 2012-05-01 | Gen Hospital Corp | High level expression of proteins |
US6924365B1 (en) * | 1998-09-29 | 2005-08-02 | Transkaryotic Therapies, Inc. | Optimized messenger RNA |
US6221349B1 (en) * | 1998-10-20 | 2001-04-24 | Avigen, Inc. | Adeno-associated vectors for expression of factor VIII by target cells |
ES2525067T3 (en) * | 2005-04-07 | 2014-12-17 | The Trustees Of The University Of Pennsylvania | Method of increasing the function of an AAV vector |
WO2007149852A2 (en) * | 2006-06-19 | 2007-12-27 | Asklepios Biopharmaceutical, Inc. | Modified factor viii and factor ix genes and vectors for gene therapy |
US20120028900A1 (en) * | 2006-06-30 | 2012-02-02 | Kaufman Randal J | Method of producing factor viii proteins by recombinant methods |
CN101597616A (en) * | 2008-06-04 | 2009-12-09 | 上海同科生物科技有限公司 | A kind of method that improves expression quantity of gene recombinant human coagulation factor 8 |
AU2013202564B2 (en) * | 2008-06-24 | 2015-09-17 | Csl Behring Gmbh | Factor VIII, von Willebrand factor or complexes thereof with prolonged in vivo half-life |
GB0911870D0 (en) * | 2009-07-08 | 2009-08-19 | Ucl Business Plc | Optimised coding sequence and promoter |
DK2482841T4 (en) * | 2009-10-02 | 2022-10-24 | Childrens Hospital Philadelphia | COMPOSITIONS AND METHODS FOR IMPROVING COAGULATION FACTOR VIII FUNCTION |
EP3404105A1 (en) * | 2012-07-06 | 2018-11-21 | Bioverativ Therapeutics Inc. | Cell line expressing single chain factor viii polypeptides and uses thereof |
AU2013336601B2 (en) * | 2012-10-26 | 2018-01-25 | Vrije Universiteit Brussel | Vector for liver-directed gene therapy of hemophilia and methods and use thereof |
SI3889173T1 (en) * | 2013-02-15 | 2023-11-30 | Bioverativ Therapeutics Inc. | Optimized factor viii gene |
-
2015
- 2015-08-13 EP EP15832128.1A patent/EP3180022A4/en active Pending
- 2015-08-13 AU AU2015301598A patent/AU2015301598B2/en active Active
- 2015-08-13 SG SG11201701033QA patent/SG11201701033QA/en unknown
- 2015-08-13 US US15/503,120 patent/US11014975B2/en active Active
- 2015-08-13 BR BR112017002781A patent/BR112017002781A2/en active Search and Examination
- 2015-08-13 WO PCT/US2015/045142 patent/WO2016025764A2/en active Application Filing
- 2015-08-13 CN CN201580055574.1A patent/CN107427557B/en active Active
- 2015-08-13 CA CA2958141A patent/CA2958141A1/en active Pending
- 2015-08-13 JP JP2017507431A patent/JP2018506261A/en active Pending
-
2017
- 2017-02-10 ZA ZA2017/01039A patent/ZA201701039B/en unknown
- 2017-02-12 SA SA517380883A patent/SA517380883B1/en unknown
-
2020
- 2020-09-14 JP JP2020153781A patent/JP7237903B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
CN107427557A (en) | 2017-12-01 |
WO2016025764A2 (en) | 2016-02-18 |
WO2016025764A3 (en) | 2016-04-07 |
SA517380883B1 (en) | 2021-12-18 |
AU2015301598B2 (en) | 2020-07-16 |
EP3180022A4 (en) | 2019-02-20 |
EP3180022A2 (en) | 2017-06-21 |
JP2018506261A (en) | 2018-03-08 |
CN107427557B (en) | 2022-01-04 |
US20170233456A1 (en) | 2017-08-17 |
AU2015301598A1 (en) | 2017-03-23 |
ZA201701039B (en) | 2021-08-25 |
CA2958141A1 (en) | 2016-02-18 |
JP2021003120A (en) | 2021-01-14 |
BR112017002781A2 (en) | 2017-12-19 |
JP7237903B2 (en) | 2023-03-13 |
US11014975B2 (en) | 2021-05-25 |
KR20170084012A (en) | 2017-07-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA201701039B (en) | An improved expression cassette for packaging and expression of variant factor viii for the treatment of hemostasis disorders | |
HK1243901A1 (en) | Devices and methods for ablation of the skin | |
EP3212191A4 (en) | Treatment for depression and depressive disorders | |
EP3995086C0 (en) | Medical device for modification of left atrial appendage | |
EP3164080A4 (en) | Methods and devices for surgical access | |
EP3151797A4 (en) | Methods and devices for treating the skin | |
EP3193795A4 (en) | Devices and methods for the removal of lenticular tissue | |
IL248538A0 (en) | Adenoassociated virus vectors for the treatment of lysosomal storage disorders | |
EP3256218A4 (en) | Kdm1a inhibitors for the treatment of disease | |
EP3171820A4 (en) | Implantable devices and techniques for oncoplastic surgery | |
HK1244485A1 (en) | Combinations for the treatment of neuroblastoma | |
PL3247459T3 (en) | Device for the ultrasound treatment of open wounds | |
HK1232220A1 (en) | Derivatives of 5-benzylisoquinoline for the treatment of cardiovascular diseases 5- | |
IL248210A0 (en) | Methods and compositions for the treatment of vascular malformation | |
EP3258930A4 (en) | Oxabicycloheptanes and oxabicycloheptenes for the treatment of depressive and stress disorders | |
IL251736B (en) | Methods and compositions for the treatment of radiation-related disorders | |
GB201423272D0 (en) | The combination for anti-wrinkle and soothing the skin | |
IL249502B (en) | Novel therapeutic uses of benzylideneguanidine derivatives for the treatment of proteopathies | |
PL3023210T3 (en) | Method for the treatment of distributable goods | |
ZA201700008B (en) | Device for medical thermotherapy | |
IL248494A0 (en) | Methods and compositions for treatment of lipid storage disorders | |
EP3200795A4 (en) | Use of agents for treating fat-related disorders | |
EP3145525A4 (en) | Use of microperoxidases for the treatment of carboxyhemoglobinemia | |
ZA201700007B (en) | Device for medical thermotherapy | |
CA3237630A1 (en) | An improved expression cassette for packaging and expression of variant factor viii for the treatment of hemostasis disorders |